Senti Biosciences, Inc. - SNTI STOCK NEWS

Senti Biosciences (Nasdaq: SNTI) has announced new employment inducement grants approved by its Compensation Committee on November 26, 2024. The committee granted stock options to three new employees to purchase a total of 49,778 shares of company common stock at an exercise price of $2.11 per share. These grants were made under the company's 2022 Inducement Equity Plan, which was adopted on August 5, 2022, and are in accordance with NASDAQ Listing Rule 5635(c)(4) as inducement material for new employees joining the company.

Senti Biosciences (Nasdaq: SNTI) has secured a $37.6 million private placement financing through the sale of 16,713 shares of Series A Convertible Preferred Stock. The PIPE financing, led by Celadon Partners with participation from NEA, Leaps by Bayer, and others, is expected to close by December 5, 2024. Investors will receive warrants to purchase up to 25,069,500 common stock shares, subject to stockholder approval. An additional option for $10 million in Preferred Stock was granted to one investor. The proceeds will fund the SENTI-202 program development, manufacturing scale-up, and general corporate purposes.

Senti Biosciences (NASDAQ: SNTI) reported positive initial clinical data from Phase 1 trial of SENTI-202, a Logic Gated CAR-NK cell therapy for relapsed/refractory hematologic malignancies including AML. Two out of three patients achieved MRD negative complete remission at the lowest dose level (1.0 billion CAR+ NK cells per dose). Both patients maintain remission after 4+ and 3+ months respectively. The therapy was generally well-tolerated with no dose limiting toxicities. SENTI-202 is designed to selectively target CD33 and/or FLT3-expressing malignancies while sparing healthy bone marrow cells. The trial continues with dose escalation, and additional response and durability data are expected in 2025.

Senti Biosciences (NASDAQ: SNTI) has appointed Fran Schulz to its Board of Directors and as chairperson of the Board's Audit Committee. Schulz, a founding member of Ernst & Young's Life Sciences Practice, brings over 35 years of experience and has been involved in over 100 equity and debt transactions totaling more than $15 billion. She has extensive expertise in finance, strategic planning, and corporate transactions in the life sciences industry. The appointment coincides with Dr. Omid Farokhzad's departure from the Board. Schulz currently serves on the boards of EDAP TMS SA and Menlo College as Audit Committee Chair.

Senti Biosciences (NASDAQ: SNTI) reported Q3 2024 financial results and pipeline updates. The company continues patient dosing in Phase 1 trial of SENTI-202 for relapsed/refractory hematologic malignancies, with initial data expected by end of 2024. Through November 2024, Senti received $4.9M of an $8M CIRM grant. Financial highlights include cash position of $10.5M, R&D expenses of $8.7M (down from $9.1M in Q3 2023), and G&A expenses of $6.2M (down from $9.4M). Net loss was $28.9M or $(6.31) per share. The company's partner Celest plans to initiate SENTI-301A trials in China in Q4 2024.

Senti Biosciences (Nasdaq: SNTI), a biotechnology company specializing in next-generation cell and gene therapies, has announced its participation in two upcoming investor conferences. The company will be present at:

1. H.C. Wainwright's 26th Annual Global Investment Conference in New York, NY, with a pre-recorded presentation available from September 9, 2024, at 7:00 a.m. ET.

2. Chardan's 8th Annual Genetic Medicines Conference in New York, NY, featuring a fireside chat on September 30, 2024, at 5:00 p.m. ET.

Senti Bio's flagship product, SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy, is currently in Phase 1 clinical trials. Investors can access webcasts and replays through the company's website for approximately 90 days following each event.

Senti Biosciences (Nasdaq: SNTI) reported Q2 2024 results and pipeline updates. Key highlights include:

• Ongoing patient dosing in Phase 1 trial of SENTI-202 for relapsed/refractory hematologic malignancies including AML
• Commencement of $8 million CIRM grant for SENTI-202 clinical development
• Plans to initiate pilot trial of SENTI-301A for HCC in China through Celest partnership in Q4 2024
• Q2 2024 financial results: $15.9 million cash, $9.2 million R&D expenses, $4.2 million G&A expenses, $11.2 million net loss
• Completed 1-for-10 reverse stock split to maintain Nasdaq listing compliance

Initial SENTI-202 efficacy data expected by year-end 2024, with durability data in 2025.

Senti Biosciences (Nasdaq: SNTI) has secured an $8 million grant from the California Institute for Regenerative Medicines (CIRM) to support the clinical development of SENTI-202. This investigational cell therapy is a potential first-in-class Logic Gated off-the-shelf CAR-NK treatment for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The Phase 1 clinical trial (NCT06325748) is currently enrolling adult patients with r/r CD33 and/or FLT3 expressing hematologic malignancies in the United States and Australia. Senti Bio expects to receive the first tranche of the grant in August 2024 and anticipates initial efficacy data by year-end 2024, with durability data following in 2025.

Senti Biosciences (Nasdaq: SNTI) has announced a 1-for-10 reverse stock split effective July 17, 2024, at 11:59 p.m. EDT. Trading on a split-adjusted basis will begin on July 18, 2024. This move will reduce outstanding shares from approximately 45.8 million to 4.6 million. The reverse split aims to address Nasdaq's minimum bid price requirement of $1.00 per share, which SNTI has not met since August 2023. Senti Bio has until August 5, 2024, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The company believes this action will increase its stock price and resolve the compliance issue.